Simioni N, et al. - Subgroups of patients with type 2 diabetes who are most likely to respond to liraglutide treatment were studied. Of the patients, 43.5% achieved a HbA1c reduction ≥ 1.0% after 12 months of treatment. The glycemic response to liraglutide was largely driven by baseline HbA1c levels, and to a lesser extent, the duration of diabetes.